21 June 2021: Editorial
Editorial: Revised World Health Organization (WHO) Terminology for Variants of Concern and Variants of Interest of SARS-CoV-2
Dinah V. ParumsDOI: 10.12659/MSM.933622
Med Sci Monit 2021; 27:e933622
Abstract
ABSTRACT: The global pandemic of coronavirus disease 2019 (COVID-19) has identified thousands of genome sequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On 31st May 2021, the Virus Evolution Working Group of the World Health Organization (WHO) announced its recommendations for revised naming of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs). This new nomenclature system may improve infection monitoring, infection control, and sharing of research data on viral genomics and epidemiology. This Editorial aims to present an update on the current revised WHO terminology for the genomic VOCs and VOIs of SARS-CoV-2.
Keywords: COVID-19, Epidemiology, Viral Variant, nomenclature, Variant of Concern, Variant of Interest, Coronavirus Disease 2019, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Editorial, COVID-19, Genomics, Pandemics, Phylogeny, Terminology as Topic, World Health Organization
The global pandemic of COVID-19 due to SARS-CoV-2 infection has identified thousands of genome sequences of the virus [1,2]. SARS-CoV-2 has a linear positive-sense RNA genome and continually adapts by random genome mutations as part of natural selection. Only a few SARS-CoV-2mutations may provide a selective advantage that may allow the virus to evade the host immune response or resist antiviral drugs, or increase transmissibility. In the past 18 months, there has been a lack of a coherent scheme for naming variants of concern (VOCs) and variants of interest (VOIs) of SARS-CoV-2. Three scientific nomenclature systems have been used to identify and track SARS-CoV-2 genotypes, including the Global Initiative on Sharing All Influenza Data (GISAID), Nextstrain, and Pango [3]. The most common scientific nomenclature has used the Pango virus nomenclature of active phylogenetic virus lineages based on the influenza virus naming system [3].
Since the beginning of the COVID-19 pandemic, the WHO COVID-19 Reference Laboratory Network has been tracking SARS-CoV-2 mutations, and in June 2020, the WHO Virus Evolution Working Group was established to monitor SARS-CoV-2 variants [4]. On 31st May 2021, the Virus Evolution Working Group of the World Health Organization (WHO) announced its recommendations for naming SARS-CoV-2 VOCs and VOIs [4–6].
A SARS-CoV-2 VOC shows increased transmissibility, more severe disease, a significant reduction in immune response from previous infection or vaccination, reduced treatment effectiveness, or reduced diagnostic detection (Table 1) [5,6]. A SARS-CoV-2 VOI has specific genetic markers predicted to affect viral transmission, diagnosis, treatment, or response to vaccines and may require increased public health measures (Table 2) [5]. The US Centers for Disease Control and Prevention (CDC) includes a third category of a variant of high consequence (VOHC) [7]. Although these variants await identification, a SARS-CoV-2 VOHC includes VOCS that have demonstrated diagnostic failure, reduction in vaccine effectiveness with vaccine breakthrough cases, and more severe clinical disease with increased hospitalizations [7].
The WHO continues to track new genomic variants of SARS-CoV-2 and determines when VOIs should be reclassified as VOCs [5,8]. An advantage of the new WHO nomenclature is that it is a simple and clear alternative to using geographical names that may stigmatize and are irrelevant to viral variants that are likely to become global and endemic [1,7]. A further advantage is that global surveillance monitoring and the assignment of VOCs may be improved by clarity in terminology [7,8]. Future variants will require other alphabets, as Greek letters may cause confusion when translated into other languages. Also, the WHO has now used ten of its 24 letters to describe four VOCs (Table 1) and six VOIs (Table 2), identified since December 2020 [5].
Conclusions
From 31st May 2021, the new system for naming and identifying more pathogenic or transmissible genomic variants of SARS-CoV-2 may benefit infection monitoring, infection control, and sharing global epidemiological research data.
References
1. World Health Organization (WHO): Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health January 8, 2021, Geneva, World Health Organization https://www.who.int/publications/i/item/9789240018440
2. Furuse Y, Genomic sequencing effort for SARS-CoV-2 by country during the pandemic: Int J Infect Dis, 2021; 103; 305-7
3. Rambaut A, Holmes EC, O’Toole Á, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology: Nat Microbiol, 2020; 5(11); 1403-7
4. World Health Organization (WHO): WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern May 31, 2021 https://www.who.int/news/item/31-05-2021-who-announces-simple-easy-to-say-labels-for-sars-cov-2-variants-of-interest-and-concern
5. World Health Organization (WHO): Tracking SARS-CoV-2 Variants May 31, 2021 https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
6. Konings F, Perkins MD, Kuhn JH, SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse: Nat Microbiol Jun 9, 2021, doi: 10.1038/s41564-021-0093-2-w [Online ahead of print]
7. Centers for Disease Control and Prevention (CDC): SARS-CoV-2 variant classifications and definitions June 10, 2021 https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
8. Lauring AS, Hodcroft EB, Genetic variants of SARS-CoV-2 – What Do They Mean?: JAMA, 2021; 325(6); 529-31
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952